File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/bcp.13705
- Scopus: eid_2-s2.0-85053373289
- PMID: 29971804
- WOS: WOS:000446824300011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: An evidence‐based systematic review of the off‐label uses of lisinopril
Title | An evidence‐based systematic review of the off‐label uses of lisinopril |
---|---|
Authors | |
Keywords | ACE inhibitor diabetes diabetic nephropathy left ventricular hypertrophy nephropathy |
Issue Date | 2018 |
Publisher | Wiley-Blackwell Publishing Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2125 |
Citation | British Journal of Clinical Pharmacology, 2018, v. 84 n. 11, p. 2502-2521 How to Cite? |
Abstract | Aims: Lisinopril is an angiotensin-converting-enzyme inhibitor that is largely administered for off-label uses. This study aims to provide a comprehensive review of off-label uses of lisinopril to aid physicians to make evidence-based decisions. Methods: The following bibliographic databases were searched from inception up to 30 March 2017: PubMed, EMBASE, the Cochrane Library, Cochrane Central Register of Controlled Trials, Scopus, Ovid and Proquest. This systematic review sought all randomized trials conducted on adult individuals comparing lisinopril on its off-label uses with alternative drugs or placebos and reported direct or alternative clinical outcomes. Risk of bias assessment by using the Cochrane Collaboration risk-of-bias tool and quality evaluation took place. Results: Included studies demonstrated significant positive effects of lisinopril on proteinuric kidney disease; however, lisinopril caused a slight reduction of glomerular filtration rate (GFR) especially for patients with GFR < 90 ml min–1. Lisinopril offered better outcomes in comparison to other standard treatments of diabetic nephropathy. Other studies showed positive effects of lisinopril for migraine, prevention of diabetes, myocardial fibrosis, mitral valve regurgitation, cardiomyopathy in patients with Duchenne muscular dystrophy, oligospermia and infertility, and diabetic retinopathy. Conversely, the studies reported that lisinopril was ineffective for five other off-label uses. Conclusions: The identified studies showed that lisinopril was highly effective for proteinuric kidney disease with a minor but inconsiderable decrease in GFR. Positive effects of lisinopril were demonstrated in seven other off-label uses; however, lisinopril cannot be recommended as the first choice for these until further clinical trials confirm these positive effects. © 2018 The British Pharmacological Society |
Persistent Identifier | http://hdl.handle.net/10722/275090 |
ISSN | 2023 Impact Factor: 3.1 2023 SCImago Journal Rankings: 1.046 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sadat‐Ebrahimi, SR | - |
dc.contributor.author | Parnianfard, N | - |
dc.contributor.author | Vahed, N | - |
dc.contributor.author | Babaei, H | - |
dc.contributor.author | Ghojazadeh, M | - |
dc.contributor.author | Tang, S | - |
dc.contributor.author | Azarpazhooh, A | - |
dc.date.accessioned | 2019-09-10T02:35:15Z | - |
dc.date.available | 2019-09-10T02:35:15Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | British Journal of Clinical Pharmacology, 2018, v. 84 n. 11, p. 2502-2521 | - |
dc.identifier.issn | 0306-5251 | - |
dc.identifier.uri | http://hdl.handle.net/10722/275090 | - |
dc.description.abstract | Aims: Lisinopril is an angiotensin-converting-enzyme inhibitor that is largely administered for off-label uses. This study aims to provide a comprehensive review of off-label uses of lisinopril to aid physicians to make evidence-based decisions. Methods: The following bibliographic databases were searched from inception up to 30 March 2017: PubMed, EMBASE, the Cochrane Library, Cochrane Central Register of Controlled Trials, Scopus, Ovid and Proquest. This systematic review sought all randomized trials conducted on adult individuals comparing lisinopril on its off-label uses with alternative drugs or placebos and reported direct or alternative clinical outcomes. Risk of bias assessment by using the Cochrane Collaboration risk-of-bias tool and quality evaluation took place. Results: Included studies demonstrated significant positive effects of lisinopril on proteinuric kidney disease; however, lisinopril caused a slight reduction of glomerular filtration rate (GFR) especially for patients with GFR < 90 ml min–1. Lisinopril offered better outcomes in comparison to other standard treatments of diabetic nephropathy. Other studies showed positive effects of lisinopril for migraine, prevention of diabetes, myocardial fibrosis, mitral valve regurgitation, cardiomyopathy in patients with Duchenne muscular dystrophy, oligospermia and infertility, and diabetic retinopathy. Conversely, the studies reported that lisinopril was ineffective for five other off-label uses. Conclusions: The identified studies showed that lisinopril was highly effective for proteinuric kidney disease with a minor but inconsiderable decrease in GFR. Positive effects of lisinopril were demonstrated in seven other off-label uses; however, lisinopril cannot be recommended as the first choice for these until further clinical trials confirm these positive effects. © 2018 The British Pharmacological Society | - |
dc.language | eng | - |
dc.publisher | Wiley-Blackwell Publishing Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2125 | - |
dc.relation.ispartof | British Journal of Clinical Pharmacology | - |
dc.rights | Preprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. | - |
dc.subject | ACE inhibitor | - |
dc.subject | diabetes | - |
dc.subject | diabetic nephropathy | - |
dc.subject | left ventricular hypertrophy | - |
dc.subject | nephropathy | - |
dc.title | An evidence‐based systematic review of the off‐label uses of lisinopril | - |
dc.type | Article | - |
dc.identifier.email | Tang, S: scwtang@hku.hk | - |
dc.identifier.authority | Tang, S=rp00480 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1111/bcp.13705 | - |
dc.identifier.pmid | 29971804 | - |
dc.identifier.pmcid | PMC6177695 | - |
dc.identifier.scopus | eid_2-s2.0-85053373289 | - |
dc.identifier.hkuros | 303442 | - |
dc.identifier.volume | 84 | - |
dc.identifier.issue | 11 | - |
dc.identifier.spage | 2502 | - |
dc.identifier.epage | 2521 | - |
dc.identifier.isi | WOS:000446824300011 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 0306-5251 | - |